Supriya Lifescience Ltd disclosed that its General Manager, Sales & Marketing, Sreekant Sreedharan, has been granted judicial custody until July 17, 2026. The Special Investigation and Intelligence branch of the Customs Department initiated an investigation against the officer on July 3, 2026, under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The proceedings relate to an alleged procedural lapse for a single export transaction of an identified product.

The company stated that based on currently available information, the legal proceedings are not expected to have a material impact on its operations, financial position, or governance. Supriya Lifescience is evaluating the implications of the case and obtaining appropriate legal advice. The matter is currently before the competent court, and the company intends to take appropriate action after examining all applicable legal provisions.

The disclosure was made to the stock exchanges in accordance with Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and a SEBI circular dated July 13, 2023.

Details of the Proceedings

The following table outlines the key details of the case as provided in the regulatory filing:

Supriya Lifescience affirmed its commitment to maintaining high standards of corporate governance and regulatory compliance. The company is closely monitoring developments and will disclose any further material information to the exchanges in accordance with applicable laws.

Supriya Lifescience Limited disclosed on April 7, 2026, that its promoters and members of the promoter group have not encumbered any shares directly or indirectly during the financial year ended March 31, 2026. This declaration, submitted to the Bombay Stock Exchange and the National Stock Exchange, confirms that the shareholding of the promoter group remains free of any charges or liens, ensuring stability in the ownership structure.

The disclosure was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The regulation requires promoters to inform the exchanges if they have pledged their shares as collateral or created any other encumbrance during a financial year. The absence of such encumbrance indicates that the promoters have not utilized their shareholding for raising external funds during the specified period.

The filing was made on behalf of the promoter, Satish Waman Wagh, and the members of the promoter group. The list of individuals and entities comprising the promoter group includes family members and various private limited companies associated with the promoters.

The following table details the names of the promoters and members of the promoter group as disclosed in the filing:

The document was digitally signed by Satish Waman Wagh on April 7, 2026. A copy of the disclosure was also forwarded to the Audit Committee of Supriya Lifescience Limited for its records.